stockrow
Friday 6 November 2026
Export NORD’s income statement to Excel — free account
Nordicus Partners Corporation
NORD Healthcare Biotechnology
Nordicus Partners Corporation’s revenue for fiscal 2025 (year ended March 2025) was $5,000.00, up 100.0% from fiscal 2024.
- Revenue
- −99.6%
- EPS
- −85.7%
- Free cash flow
- +62.2%
Quarter to June 2026, against a year earlier
3.40
0.33
−8.85%
Follow NORD
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
0.00 | 0.02 | 0.21 | 0.24 | |
Current Ratio |
0.18 | 0.46 | 0.71 | 0.48 | |
Net Debt/EBITDA |
0.01 | 0.02 | 0.17 | 0.20 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.07 | 12.03 | 1.19 | 1.17 | |
Capex/Depreciation |
(0.92) | 1.13 | (0.35) | (54.00) | |
Interest Coverage |
(431.37) | (3,013.75) | (5,611.00) | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.37 | 0.36 | 0.36 | 0.37 | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.01) | (0.04) | (0.08) | (0.10) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.01) | (0.04) | (0.08) | (0.10) | |
Cash per Share |
0.00 | 0.00 | 0.01 | 0.01 | |
Shareholders Equity per Share |
3.21 | 3.54 | 3.48 | 3.62 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.21 | 3.54 | 3.48 | 3.62 | |
Free Cash Flow |
(0.16) | (0.67) | (1.46) | (1.77) | |
Working Capital |
(1.37) | (0.64) | (0.26) | (0.52) | |
Capital Expenditures |
0.00 | 0.00 | 0.00 | (0.01) | |
Net Current Asset Value |
(11.29) | (10.69) | (10.46) | (10.73) | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
1.60 | 1.09 | 0.76 | 0.58 | |
Average Assets |
74.61 | 72.85 | 67.79 | 48.33 | |
Average Common Equity |
62.89 | 62.05 | 61.79 | 42.65 |
Columns are period end dates · fundamentals updated 2 Nov 2026